MedTrace Logo

Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure

NCT00252187 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2012-12-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of subcutaneous injection of Human BNP (nesiritide), a hormone produced by the heart, on the pumping ability of the heart, kidney function, and hormonal function in persons with heart failure.

Conditions

Interventions

DRUG

B-type Natriuretic Peptide (BNP)

BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.

OTHER

Placebo

Placebo self-administered subcutaneously twice daily for 8 weeks.

Sponsors & Collaborators

  • American Heart Association

    collaborator OTHER

  • Scios, Inc.

    collaborator INDUSTRY

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Horng Chen

    lead OTHER

Principal Investigators

  • Horng H. Chen, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2008-07-31
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252187 on ClinicalTrials.gov